AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $233.01 billion. The enterprise value is $259.54 billion.
Market Cap | 233.01B |
Enterprise Value | 259.54B |
Important Dates
The last earnings date was Thursday, April 25, 2024, before market open.
Earnings Date | Apr 25, 2024 |
Ex-Dividend Date | Feb 22, 2024 |
Share Statistics
AstraZeneca has 3.10 billion shares outstanding.
Shares Outstanding | 3.10B |
Owned by Insiders (%) | 0.01% |
Owned by Institutions (%) | 16.84% |
Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 37.28 and the forward PE ratio is 16.31. AstraZeneca's PEG ratio is 0.89.
PE Ratio | 37.28 |
Forward PE | 16.31 |
PS Ratio | 4.89 |
Forward PS | 4.41 |
PB Ratio | 6.22 |
P/FCF Ratio | 28.32 |
PEG Ratio | 0.89 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.22, with an EV/FCF ratio of 31.55.
EV / Earnings | 41.00 |
EV / Sales | 5.45 |
EV / EBITDA | 18.22 |
EV / EBIT | 28.51 |
EV / FCF | 31.55 |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 0.92.
Current Ratio | 0.89 |
Quick Ratio | 0.69 |
Debt / Equity | 0.92 |
Debt / EBITDA | 2.43 |
Debt / FCF | 4.20 |
Interest Coverage | 5.44 |
Financial Efficiency
Return on equity (ROE) is 16.80% and return on invested capital (ROIC) is 10.37%.
Return on Equity (ROE) | 16.80% |
Return on Assets (ROA) | 6.40% |
Return on Capital (ROIC) | 10.37% |
Revenue Per Employee | $529,600 |
Profits Per Employee | $70,423 |
Employee Count | 89,900 |
Asset Turnover | 0.48 |
Inventory Turnover | 1.67 |
Taxes
In the past 12 months, AstraZeneca has paid $1.10 billion in taxes.
Income Tax | 1.10B |
Effective Tax Rate | 14.80% |
Stock Price Statistics
The stock price has increased by +2.25% in the last 52 weeks. The beta is 0.19, so AstraZeneca's price volatility has been lower than the market average.
Beta (1Y) | 0.19 |
52-Week Price Change | +2.25% |
50-Day Moving Average | 67.17 |
200-Day Moving Average | 66.80 |
Relative Strength Index (RSI) | 82.17 |
Average Volume (30 Days) | 6,384,256 |
Short Selling Information
Short Interest | 8.58M |
Short Previous Month | 7.66M |
Short % of Shares Out | 0.27% |
Short % of Float | n/a |
Short Ratio (days to cover) | 1.61 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $47.61 billion and earned $6.33 billion in profits. Earnings per share was $2.03.
Revenue | 47.61B |
Gross Profit | 39.03B |
Operating Income | 8.76B |
Pretax Income | 7.43B |
Net Income | 6.33B |
EBITDA | 14.25B |
EBIT | 9.11B |
Earnings Per Share (EPS) | $2.03 |
Balance Sheet
The company has $8.02 billion in cash and $34.55 billion in debt, giving a net cash position of -$26.53 billion or -$8.56 per share.
Cash & Cash Equivalents | 8.02B |
Total Debt | 34.55B |
Net Cash | -26.53B |
Net Cash Per Share | -$8.56 |
Equity / Book Value | 37.45B |
Book Value Per Share | 12.08 |
Working Capital | -3.31B |
Cash Flow
In the last 12 months, operating cash flow was $9.70 billion and capital expenditures -$1.47 billion, giving a free cash flow of $8.23 billion.
Operating Cash Flow | 9.70B |
Capital Expenditures | -1.47B |
Free Cash Flow | 8.23B |
FCF Per Share | $2.66 |
Margins
Gross margin is 81.98%, with operating and profit margins of 18.40% and 13.30%.
Gross Margin | 81.98% |
Operating Margin | 18.40% |
Pretax Margin | 15.61% |
Profit Margin | 13.30% |
EBITDA Margin | 29.92% |
EBIT Margin | 19.12% |
FCF Margin | 17.28% |
Dividends & Yields
This stock pays an annual dividend of $1.45, which amounts to a dividend yield of 1.93%.
Dividend Per Share | $1.45 |
Dividend Yield | 1.93% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 76.12% |
Buyback Yield | n/a |
Shareholder Yield | 1.93% |
Earnings Yield | 2.72% |
FCF Yield | 3.53% |
Analyst Forecast
The average price target for AstraZeneca is $82.33, which is 9.53% higher than the current price. The consensus rating is "Buy".
Price Target | $82.33 |
Price Target Difference | 9.53% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | 6.69% |
EPS Growth Forecast (5Y) | 25.82% |
Stock Splits
The last stock split was on July 27, 2015. It was a forward split with a ratio of 2:1.
Last Split Date | Jul 27, 2015 |
Split Type | Forward |
Split Ratio | 2:1 |
Scores
AstraZeneca has an Altman Z-Score of 2.88 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.88 |
Piotroski F-Score | 6 |